Login to Your Account

AM-Pharma Banks $40M for Acute Kidney Injury Drug

By Cormac Sheridan

Wednesday, September 14, 2011
AM-Pharma BV banked €29.2 million (US$39.8 million) in a Series D round, which, to its knowledge, is the biggest ever venture capital financing in Dutch biotechnology. The company will use the proceeds to effect a switch from a bovine to a recombinant form of alkaline phosphatase, which is in development for treatment of acute kidney injury. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription